Hepatorenal Syndrome Treatment Market by Type, Treatment, End-User - Global Forecast 2025-2030- Product Image

Sale

Hepatorenal Syndrome Treatment Market by Type, Treatment, End-User - Global Forecast 2025-2030

Report
181 Pages
October 2024
Region: Global
360iResearch™
ID: 5336349

UP TO €692EUR$697USD£574GBP OFF until Dec 31^st 2024

The Hepatorenal Syndrome Treatment Market grew from USD 4.56 billion in 2023 to USD 4.80 billion in 2024. It is expected to continue growing at a CAGR of 5.47%, reaching USD 6.62 billion by 2030.

Hepatorenal Syndrome (HRS) is a life-threatening condition that involves rapidly declining kidney function in individuals with severe liver damage, often cirrhosis. The market for treating HRS is focused on lifesaving pharmaceuticals, devices, and supportive treatments such as liver transplants. The necessity of effective HRS treatments is driven by the severe outcomes associated with the syndrome, necessitating interventions that restore kidney function and improve survival rates. The application scope includes hospitals and specialty clinics where therapies like albumin, vasoconstrictors, and novel agents are administered. The end-use scope ranges from healthcare providers to transplant centers. Market growth is significantly influenced by increasing prevalence rates of liver diseases, advancements in diagnostic tools enabling quicker diagnosis, and a rising awareness of liver and kidney health. Opportunities emerge with the development of novel therapeutics such as synthetic vasopressin analogs and collaborations between pharmaceutical companies and research institutions for drug trials. However, growth is challenged by the complexity of HRS, which remains underdiagnosed, the high cost of treatments like liver transplants, and limited availability of viable organs. Economic barriers also restrict market expansion in lower-income regions. Innovating in non-invasive diagnostic technologies and targeted therapies holds promise for business growth, as does enhancing patient access to treatment through cost-effective solutions. Market dynamics involve a competitive landscape with ongoing research, shifting regulations, and potential mergers among stakeholders aiming for comprehensive solutions. The nature of the market is patient-centric, with a focus on personalized medicine. To capitalize on this, companies should prioritize partnerships for technology innovation, regulatory ease, and streamlined care pathways that align with evolving clinical guidelines and patient needs. Additionally, advocacy and educational efforts can raise awareness, potentially increasing early detection rates and treatment adoption.

Understanding Market Dynamics in the Hepatorenal Syndrome Treatment Market

The Hepatorenal Syndrome Treatment Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Rising prevalence of hepatorenal syndrome
- Increasing fast track and orphan drug designations
- Growing disease awareness & patient support programs
Market Restraints
- High treatment costs, and product recall incidents
Market Opportunities
- Increasing research & development to incorporate advanced technologies
- Increased funding and venture capital for biotech start-ups focusing on innovative HRS treatments
Market Challenges
- Side-effects and risks related to drug usage

Exploring Porter’s Five Forces for the Hepatorenal Syndrome Treatment Market

Porter’s Five Forces framework further strengthens the insights of the Hepatorenal Syndrome Treatment Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Hepatorenal Syndrome Treatment Market

External macro-environmental factors deeply influence the performance of the Hepatorenal Syndrome Treatment Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Hepatorenal Syndrome Treatment Market

The Hepatorenal Syndrome Treatment Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Hepatorenal Syndrome Treatment Market

The Hepatorenal Syndrome Treatment Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Hepatorenal Syndrome Treatment Market

The Hepatorenal Syndrome Treatment Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hepatorenal Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include Aetna Inc., Baxter International Inc, Becton, Dickinson and Company, Biocon Limited, BioVie Inc, Cadila Healthcare Limited, Cumberland Pharmaceuticals Inc, Edwards Lifesciences Corporation, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Mallinckrodt Inc, Medtronic plc, Neovii Pharmaceuticals AG, Novartis International AG, Orphan Therapeutics, LLC, PharmaIN Corporation, Samarth Life Sciences Pvt Ltd., Swastik Life Sciences, and United Biotech Pvt Ltd..

Market Segmentation & Coverage

This research report categorizes the Hepatorenal Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Type 1 Hepatorenal Syndrome
- Type 2 Hepatorenal Syndrome
Treatment
- Surgical Treatment
  - Liver Transplantation
  - Renal Replacement Therapy
  - Surgical Shunting
- Therapeutics
  - Glypressin
  - Lucassin
  - Terlivaz
End-User
- Academic & Research Institutes
- Ambulatory Surgical Centers
- Hospitals & Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of hepatorenal syndrome
5.1.1.2. Increasing fast track and orphan drug designations
5.1.1.3. Growing disease awareness & patient support programs
5.1.2. Restraints
5.1.2.1. High treatment costs, and product recall incidents
5.1.3. Opportunities
5.1.3.1. Increasing research & development to incorporate advanced technologies
5.1.3.2. Increased funding and venture capital for biotech start-ups focusing on innovative HRS treatments
5.1.4. Challenges
5.1.4.1. Side-effects and risks related to drug usage
5.2. Market Segmentation Analysis
5.2.1. Treatment: Ongoing innovations to improve the efficacy and treatment outcomes of surgical interventions
5.2.2. End-User: Availability of comprehensive healthcare solutions and services in hospitals and clinics
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Hepatorenal Syndrome Treatment Market, by Type

6.1. Introduction
6.2. Type 1 Hepatorenal Syndrome
6.3. Type 2 Hepatorenal Syndrome

7. Hepatorenal Syndrome Treatment Market, by Treatment

7.1. Introduction
7.2. Surgical Treatment
7.2.1. Liver Transplantation
7.2.2. Renal Replacement Therapy
7.2.3. Surgical Shunting
7.3. Therapeutics
7.3.1. Glypressin
7.3.2. Lucassin
7.3.3. Terlivaz

8. Hepatorenal Syndrome Treatment Market, by End-User

8.1. Introduction
8.2. Academic & Research Institutes
8.3. Ambulatory Surgical Centers
8.4. Hospitals & Clinics

9. Americas Hepatorenal Syndrome Treatment Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Hepatorenal Syndrome Treatment Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Hepatorenal Syndrome Treatment Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. Mallinckrodt Announces Key Study Results on TERLIVAZ for Hepatorenal Syndrome Reversal at SCCM 2023 Congress
12.3.2. FDA Approves First-Ever Treatment for Rapid Kidney Failures in Hepatorenal Syndrome
12.4. Strategy Analysis & Recommendation

List of Figures

FIGURE 1. HEPATORENAL SYNDROME TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 9. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. HEPATORENAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. HEPATORENAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. HEPATORENAL SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. HEPATORENAL SYNDROME TREATMENT MARKET DYNAMICS
TABLE 7. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE 1 HEPATORENAL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE 2 HEPATORENAL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY RENAL REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL SHUNTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GLYPRESSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY LUCASSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TERLIVAZ, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 41. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 42. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 43. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 44. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 45. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 48. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 49. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 50. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 57. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 63. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 68. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 69. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 70. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 71. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 72. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 75. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 76. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 77. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 79. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 80. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 83. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 85. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 86. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 87. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 89. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 98. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 99. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 104. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 109. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 110. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 113. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 114. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 115. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 116. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 117. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 120. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 129. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 130. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 131. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 132. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 133. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 134. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 135. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 136. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 137. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 138. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 140. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 141. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 142. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 143. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 145. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 146. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 147. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 148. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 149. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 150. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 151. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 152. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 153. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 154. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 155. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 156. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 159. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 160. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 161. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 162. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 163. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 164. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 169. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 170. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 174. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 175. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 176. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 177. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 178. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 179. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 180. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 181. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 182. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 183. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 184. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 185. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 186. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 187. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 188. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 204. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 205. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 206. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 207. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 208. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 214. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 215. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 216. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 219. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 220. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 221. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 222. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 223. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 234. HEPATORENAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 235. HEPATORENAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Hepatorenal Syndrome Treatment market, which are profiled in this report, include:

Aetna Inc.
Baxter International Inc
Becton, Dickinson and Company
Biocon Limited
BioVie Inc
Cadila Healthcare Limited
Cumberland Pharmaceuticals Inc
Edwards Lifesciences Corporation
F. Hoffmann-La Roche AG
GlaxoSmithKline plc
Mallinckrodt Inc
Medtronic plc
Neovii Pharmaceuticals AG
Novartis International AG
Orphan Therapeutics, LLC
PharmaIN Corporation
Samarth Life Sciences Pvt Ltd.
Swastik Life Sciences
United Biotech Pvt Ltd.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	181
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 4.8 Billion
Forecasted Market Value ( USD ) by 2030	$ 6.62 Billion
Compound Annual Growth Rate	5.4%
Regions Covered	Global
No. of Companies Mentioned	19

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3518EUR$3,545USD£2,919GBP €3909EUR$3,939USD£3,243GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6224EUR$6,272USD£5,164GBP €6915EUR$6,969USD£5,738GBP

Understanding Market Dynamics in the Hepatorenal Syndrome Treatment Market

Exploring Porter’s Five Forces for the Hepatorenal Syndrome Treatment Market

Applying PESTLE Analysis to the Hepatorenal Syndrome Treatment Market

Analyzing Market Share in the Hepatorenal Syndrome Treatment Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Hepatorenal Syndrome Treatment Market

Strategic Recommendations for Success in the Hepatorenal Syndrome Treatment Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Hepatorenal Syndrome Treatment Global Market Report 2024

Hepatorenal syndrome - Pipeline Insight, 2024

Nephrology. A Comprehensive Guide to Renal Medicine. Edition No. 1. Lecture Notes

Sleisenger and Fordtran's Gastrointestinal and Liver Disease Review and Assessment. Edition No. 11

Acute Kidney Injury (AKI) - Market Insight, Epidemiology and Market Forecast - 2034

About the Hepatorenal Drug Market